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Abstract
The massive genomic data from The Cancer Genome Atlas (TCGA), including proteomics
data from Clinical Proteomic Tumor Analysis Consortium (CPTAC), provides a unique
opportunity to study cancer systematically. While most observations are made from a single
type of genomics data, we apply big data analytics and systems biology approaches by
simultaneously analyzing DNA amplification, mRNA and protein abundance. Using multiple
genomic profiles, we have discovered widespread dosage compensation for the extensive
aneuploidy observed in TCGA breast cancer samples. We do identify 11 genes that show
strong correlation across all features (DNA/mRNA/protein) analogous to that of the well-
known oncogene HER2 (ERBB2). These genes are generally less well-characterized
regarding their role in cancer and we advocate their further study. We also discover that
shRNA knockdown of these genes has an impact on cancer cell growth, suggesting a vul-
nerability that could be used for cancer therapy. Our study shows the advantages of system-
atic big data methodologies and also provides future research directions.
Introduction
The scientific literature is replete with papers highlighting the complex interplay between
chromosomal instability, aneuploidy, and cancer (e.g. [1] [2] [3] [4]). Aneuploidy, the state of
having other than the canonical or “euploid” number of chromosomes—for humans, 46—is
with only rare exceptions (Downs syndrome, Trisomy 18) lethal in human embryonic devel-
opment [5]. By contrast, aneuploidy is observed with very high frequency in cancer, leading
the eminent German biologist Theodor Boveri to speculate as early as 1902 [6] that aneuploidy
might have a causative role in the disease.
Despite previous investigations, there are still important questions. Is aneuploidy a cause or
a side-effect of cancer? If the former, what factors associated with aneuploidy contribute to
cancer cell fitness? Are there deleterious impacts of aneuploidy in cancer and how are they
mitigated during tumorigenesis? More generally, what is the broader impact of aneuploidy on
gene expression and resulting phenotypes?
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DNA studies have found that amplification of genomic arms such as 20q and 8q [7] [8]
occur with high prevalence and have been correlative with cancer severity. Understanding
how these amplifications impact changes in gene expression and protein production is of great
interest. The conventional wisdom regarding gene transcription and translation has been that
“dosage” generally correlates with product: DNA to RNA to protein. Indeed, a recent report
finds no evidence for widespread dosage compensation in yeast [9].
It is customary to use mRNA transcript abundance to identify disease-associated genes, but
the impact of mRNA abundance on protein production is poorly understood. Correlational
methods yield weak associations, even when considering protein half-lives and other chemical
properties [10–13]. Other efforts have been made to integrate mRNA dynamics (half-life and
fold energy) and RNA Binding Protein (RBP) interactions with expression data in S. cerevisiae
and S. pombe to aid in predicting protein production from gene expression. [14] Illustrates
how sequence elements (sequence lengths, secondary structures, etc.) were used to identify
protein abundance variations. Understanding how DNA, RNA, and protein interact is a non-
trivial task, but considering any of these features in isolation may yield sub-optimal results.
This understanding could provide crucial details about tumorigenesis, cancer evolution, and
may hold clues to potential cancer treatments.
In 2015 approximately 40,000 women died of breast cancer in the US alone [15]. In an effort
to better profile and understand cancer, large public efforts have been initiated to gather
patient data and comprehensively investigate it. The Cancer Genome Atlas (TCGA) collects
data for patients across 34 types of cancer profiled using a wide array of ‘-omics’ platforms
[16]. The unprecedented availability of cancer data, like TCGA, affords insights into the geno-
mic foundation of these lethal diseases.
In this paper, we apply big data methods in a systematic fashion to observe the impact of
DNA dosage on mRNA transcript levels and subsequent protein concentrations. We identify
the prevalence of dosage compensation in TCGA breast cancer samples (BRCA), highlight
dosage-sensitive genes, and investigate the role of these genes in cancer cell line survival.
Material and methods
The data used in this study has been downloaded from multiple resources, including TCGA
[17], Clinical Proteomic Tumor Analysis Consortium (CPTAC) [18], the Catalogue of Somatic
Mutations in Cancer (COSMIC) [19], and Achilles short hairpin RNA or small hairpin RNA
(shRNA) [20]. The data and processing approaches are briefly described below. Fig 1 illustrates
the overall workflow.
The Cancer Genome Atlas (TCGA)
RNAseq V2 data of 114 normal control patients and 1102 patients with breast invasive carci-
noma (BRCA) were downloaded from TCGA. For each of the 20532 genes of each patient, the
median of 114 normal values was used as an estimated baseline, which is noted as the Normal
median RSEM. The fold change of each gene, Δexp(gene), was calculated for every patient as:
Dexp geneð Þ ¼ log2
Cancer RSEM ðgeneÞ
Normal median RSEMðgeneÞ
ðEq1Þ
The corresponding patient metadata was downloaded and mapped based on sample IDs
extracted from the TCGA barcode. Level 3 TCGA copy number variant (CNV) data was
extracted for all available patients. The TCGA CNV pipeline transforms a CNV value into a
segment mean, where Segment mean = log2(CNV/2). A copy number can be derived from the
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segment means by calculating 2 � (2segment mean). With this, the diploid regions will have a seg-
ment mean value of zero, amplified regions will have positive values, and deletions will have
negative values.
Clinical proteomic tumor analysis consortium (CPTAC)
Mass spectrometry (MS) data for breast invasive carcinoma was downloaded from CPTAC;
these abundances were reported as the log2-ratio of the expression of the sample to a common,
healthy pool [21]. Patient mRNA, protein, and CNV data was matched using TCGA barcode.
Gene identifications for MS data were made using previously established methods [22] and
were provided by CPTAC. mRNA, protein, and CNV data for a given gene were joined by
gene symbol. The unshared relative protein abundance was matched to 106 patients with
mRNA and protein abundance data [18].
Gene amplification and deletion
Segment regions were mapped to the UCSC genome coordinates for the hg38 build of the
human genome. For regions that covered multiple genes, the segment means counted for each
gene. For genes with multiple calls, the maximum value was kept.
For genes across all 106 samples with protein and mRNA data, we observe 1,052,345 seg-
ment means in total. The average segment mean was 0.12 ± 0.02. We define a gene as amplified
if its segment mean is greater than 0.2 and deleted if it is less than -0.2 [23]. Doing so we find
837,531 normal segments in the patients, 213,361 segments are amplified, and 1,453 have dele-
tion events. Of those, 9835 genes were uniquely identified as normal, 9831 as amplified, and
1247 as deleted. Interestingly, only 15 patients of the 106 had no deletions.
To normalize protein and mRNA expression to a similar scale, a z-score normalization for
protein and mRNA fold changes was performed as follows:
z ¼
xDexp   mDexp
dDexp
ðEq2Þ
Where xDexp represents the expression of a given gene, mDexp the mean expression for the data
set, and dDexp the standard deviation.
Cancer gene profiling
The Cancer Gene Census was downloaded from COSMIC [19]. Genes labelled as amplified
were selected and mapped to the results of the integrated genomics analysis to annotate corre-
lational signatures. The Pearson correlation coefficient was calculated between protein abun-
dance fold-change, mRNA fold-change, and CNV amplification. Any gene with all
correlational scores above 0.70 is called a “Broadly Dosage-Sensitive Gene,” or BDSG. The
stringent cutoff was selected to emphasize genes as very unique. Generally, there was poor cor-
relational concordance among the features (Fig A in S1 File and Table A in S1 File). This is not
to say the genes below this threshold may not be informative, but they are not exemplars of
this particular genomic conservation.
Fig 1. Bottom-up, integrated analysis workflow. Visual representation of the analytical workflow for identifying
broadly dosage-sensitive genes. Green portions represent mRNA-based steps, red protein, blue CNV. Integrated and
filtering steps are white. Briefly, data were acquired from their sources, joined with metadata, normalized, integrated,
then filtered.
https://doi.org/10.1371/journal.pone.0210910.g001
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Achilles shRNA
Achilles shRNA knockdown data was downloaded and subset for the BDSG genes, a selection
of housekeeping genes [24] and genes acting as oncosuppressors or oncogenes (S1 Table).
shRNA hairpins for each gene were selected based on second-lowest log-ratio to avoid false
positives. Hierarchical clustering was performed via Python clustermap function on the genes,
as well as the cell types. Additional hierarchical clustering was performed excluding any cell
types not related to breast models.
Results and discussion
Genomics and protein analysis
RSEM distributions for the 106 breast cancer patients for 20531 genes were plotted for both
the cancer and healthy samples. Initial observations of RSEM values show similar quantiles
suggesting that global expression distributions are similar between tumor-matched normal
and tumor samples (Fig B in S1 File). This alleviates concern for the impact of any batch-effect
or other temporal anomalies in sample processing.
Wilcoxon signed-rank test of gene expression between healthy and cancer samples detected
that over 10,000 genes had significantly different expression (p< 0.00005). This emphasizes
that the cancer transcriptome varies dramatically from normal tissue.
The log2 fold-change of mRNA from cancer to healthy was calculated as (Eq 1), described
with a mean mRNA fold change of -9.0�10−2 ± 1.5 (max = 17, min = – 16). The indicates a
class of genes that have minimal change and another subset that shows large changes in expres-
sion as indicated by the distribution (Fig C in S1 File).
Fold changes were plotted for protein expression. For proteins, the mean fold change was
3�10−2 ± 0.67 (max = 8.5, min = – 6.5). Since the dynamic range of these effects are not equiva-
lent in both datasets, they were z-score normalized (Fig D in S1 File). After normalization (Fig
E in S1 File), the overall distributions of mRNA and protein fold changes were not statistically
different (p = 0.96, Wilcoxon Test). Therefore, our normalization practice is sufficient to inte-
grate the datasets and attempt to find relationships. These relationships are visualized in Fig 2.
The strikingly poor correlation between the two features emphasizes the difficulty in accurately
inferring protein levels from given mRNA expression values. A D’Agostino’s K-squared test of
the mRNA and protein correlations led to the rejection of the null hypothesis that the data was
Guassian (p< 0.0005). Further examination of QQ plots conveys a trend for a mariginally
lighter left tail and a heavier right tail to the distribution (Fig F in S1 File).
mRNA and protein dysregulation relative to copy number variation
There is a strong positive trend for correlation of mRNA fold change with segment means.
This is intuitive, given if there is an amplification or deletion of a genomic region transcrip-
tional activity is impacted.
A surprising result is the volume of anti-correlated genes when comparing mRNA versus
protein fold-changes (Fig G in S1 File). There are 185 genes out of the 9835 with weak, negative
correlations between mRNA and protein fold-changes. A negative correlation suggests that a
regulatory mechanism is either additionally suppressing or enhancing transcript abundance.
We observe a number of genes which have negative correlation. These are of relatively low
magnitude and lack statistical significance, but there may be underlying biological mecha-
nisms at play that may be of interest in future studies. This notion of regulatory interactions is
emphasized again by observing the correlation of protein changes to segment means (Fig H in
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S1 File). In this case there are generally weak correlations, supporting the concept that precur-
sor genomic features are often not a reliable predictor of protein concentration [25].
Selecting genes and subsequent data based on the 20q chromosomal arm–a locus known to
be frequently-amplified in breast cancer [26] exemplifies how DNA amplification, mRNA and
protein abundance may be discordant. In the case of the gene SLPI for a sample (TCGA bar-
code: D8-A13Y), we see that there is strong DNA amplification, however mRNA and protein
abundance is very low. SLPI encodes an antibody-producing transcript which antagonizes pac-
litaxel in ovarian cancer cells [27]. Conversely, we can see cases where there is concordance
between amplification, mRNA abundance, and protein abundance. In the case of RIMS4, we
see very high fold changes and amplification in certain members of the cohort. KM-survivabil-
ity analysis [28] based on microarray data of over 1000 breast cancer patients indicates that
high RIMS4 expression has a positive prognostic impact (P<4.0x10-7).
Cancer gene profiling identifies broadly dosage-sensitive genes (BDSGs)
The mRNA, protein, and CNV data for genes labeled as amplified in breast cancer from COS-
MIC is in Fig 3A. Genes from across the genome that meet the Pearson correlation criteria
(i.e., all correlations above 0.75) are displayed in Fig 3D and listed in Table 1. Among the genes
in Table 1, ERBB2 (HER2, Fig 3C) is a member of this group and is a well-known oncogene.
In both Fig 3C and Fig 3D, we observe a strong dosage sensitivity that is atypical across the
genome. The remaining 11 genes in Fig 3D are not identified in COSMIC at all. GRB7 is a
growth factor receptor that overlaps with HER2 pathways, and coexpresses with it in
Fig 2. mRNA fold change versus protein fold change. This represents the matched protein (y-axis) and mRNA (x-axis) z-score
normalized, log2 fold changes of disease to healthy samples for 106 patients and 20531 genes. Poor correlation amongst the points suggests
that mRNA changes do not necessarily predict protein production changes.
https://doi.org/10.1371/journal.pone.0210910.g002
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esophageal cancer [29]. RPS6KB1 is a kinase whose alterations have been associated with an
increased risk of colorectal cancer [30]. These broadly dosage-sensitive genes (BDSGs) are
observations on a seemingly rare conservation of the central dogma, yet they have minimal
functional annotations in the scientific literature.
shRNA data defines the role of BDSGs in cancer cell line growth
Fig 4 shows results of testing the impact of BDSGs on cancer cell line growth using shRNA.
TUBB is a common housekeeping gene and the signature illustrated in 4a is typical of this role.
Fig 3. Protein vs mRNA fold changes with CNV amplification. Figures represent the z-score normalized, log2 fold change of mRNA (x-axis) versus protein (y-axis)
and are colored by CNV segment mean values for samples from patients in the TCGA Breast Cancer dataset selected for: (a) Genes in the COSMIC database labelled as
amplified, (b) known oncogene MYC, (c) known oncogene and BDSG HER2/ERBB2, and (d) all BDSGs. The trend in Fig 3A exemplifies how oncogenecity does not
always correlate with dosage-sensitivity.
https://doi.org/10.1371/journal.pone.0210910.g003
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When knocked down by shRNA there is a very deleterious effect on cancer cell line growth
and it stands out as a singleton in both heatmaps. In Fig 4A we observe that PPME1 and
UBE2Z consistently behave as tumor suppressor genes (TSGs) across all cell types; their silenc-
ing promotes cell viability. In breast cancer cell lines these genes cluster closely with PTEN and
RB1 which were included as typical breast cancer TSGs. In contrast, GRB7 and RPS6KB1 have
a generally negative impact on cell line viability in Fig 4A. However, when considering just
breast cancer-specific cell lines, we observe that these genes cluster closely and exclusively with
ERBB2. The differences in clustering behavior suggest that, unlike PPME1 and UBE2Z, GRB7
and RPS6KB1 act as oncogenes very similar to ERBB2. In fact, GRB7 is co-located with ERBB2
and may be upregulated as an adaptation to HER2 [29]. According to the breast-specific cell
type clustering of shRNA data, BDSGs do not display a subtype-specific role. They are gener-
ally tumor suppressors or oncogenes across all breast cell lines.
Conclusions
In this paper we have shown that in the TCGA breast cancer cohort there is widespread dosage
compensation for the extensive aneuploidy that is observed. The dosage of DNA does not gen-
erally correlate well with mRNA, nor does the latter correlate well with protein levels. A total
of 11 genes show strong correlation across all features (DNA/mRNA/protein); analogous to
that of a well-known oncogene HER2 (ERBB2). We refer to these genes as “Broadly Dosage-
Sensitive Genes” or BDSGs. We note they are much less characterized in the literature as to
their role, if any, in cancer. We advocate further study of BDSGs to better understand their
potential effects on cancer. This may lead to new therapies for cancer or biomarkers for
improved cancer detection.
From shRNA data, we show that knockdown of these genes has an impact on cancer cell
growth. We speculate that tumor cells adapt unusual ploidies to take advantage of amplifica-
tions and deletions that functionally implicate only subsets of genes. These tumor cells may
compensate for the dosage of a large number of “passenger” genes. This may be a vulnerability
that could be used for cancer therapy, for example by de-repressing mRNA and/or protein
production from these passenger genes. This may leave the tumor cell with potentially cata-
strophic levels of unneeded molecules or disrupted biological pathways.
We also caution that there may be significant pitfalls in drawing conclusions from a single
type of genomics data. For example, gene expression (mRNA) data is widely-used to infer
Table 1. Broadly dosage-sensitive genes (BDSGs).
Symbol Location
ERBB2 17q11.2-q12
GBAS 7p12
GRB7 17q12
HEATR6 17q23.2
LANCL2 7q31.1-q31.33
PDSS2 6q21
PPFIA1 11q13.3
PPME1 11q13.4
RPS6KB1 17q23.1
SUMF2 7q11.1
TACO1 17q23.3
UBE2Z 17q21.32
https://doi.org/10.1371/journal.pone.0210910.t001
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biological pathway activation, but Fig 2 suggests this would be extremely misleading for
exploring protein levels of Cancer Gene Census genes in TCGA Breast samples.
Supporting information
S1 Table. House keeping, oncosuppressor, and oncogenes selected for Achilles shRNA
analysis.
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